Form 4: Arteris Inc. Insider Sells Shares Under 10b5-1 Plan

Arteris, Inc. reports significant stock sales by President and CEO K. Charles Janac, executed under a pre-arranged 10b5-1 trading plan.

Summary

• K. Charles Janac, President and CEO of Arteris, Inc., reported the sale of a substantial number of common stock shares on July 6, 2026.
• These transactions were conducted in accordance with a Rule 10b5-1 trading plan adopted on December 12, 2025.
• The sales involved multiple tranches with weighted average sale prices ranging from $34.64 to $37.58.
• Following these sales, Janac's beneficial ownership of Arteris, Inc. common stock has been adjusted.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to significant insider selling, although it was conducted under a pre-arranged plan, which mitigates concerns about opportunistic trading.

Negatives

• Significant stock sales by a key executive, K. Charles Janac, totaling tens of thousands of shares across multiple transactions.
• The sales occurred at prices ranging from $34.64 to $37.58, indicating a divestment of holdings at prevailing market rates.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a 10b5-1 plan is a common strategy for executives to diversify holdings or manage personal finances while adhering to insider trading regulations. The specific volume and pricing of these sales by a key executive like the President and CEO warrant attention from investors monitoring insider activity.

Stakeholder Impact

• Shareholders may view significant insider selling, even under a 10b5-1 plan, with caution, potentially impacting short-term stock sentiment.
• Employees holding stock options or grants may be influenced by the executive's divestment decisions.

Key Dates

Recommendation

The filing reports routine stock sales by an executive under a pre-established 10b5-1 plan. While significant selling by a CEO can be a concern, the structured nature of the plan suggests it's not necessarily a reflection of negative company outlook. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Arteris, Inc.'s performance and strategic direction.

Keywords

Arteris Inc., K. Charles Janac, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Beneficial Ownership